Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models
about
Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell linesMarine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.Highlights of marine invertebrate-derived biosynthetic products: their biomedical potential and possible production by microbial associantsMarine Peptides: Bioactivities and ApplicationsChemistry and biology of kahalalides.Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compoundDifferential effect of grape seed extract against human non-small-cell lung cancer cells: the role of reactive oxygen species and apoptosis induction.Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid raftsPhase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial).Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides.Marine natural product peptides with therapeutic potential: Chemistry, biosynthesis, and pharmacology.A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors.Marine Peptides and Proteins with Cytotoxic and Antitumoral Properties
P2860
Q28484892-A00EBA90-2B9B-485C-ADC9-3EF4CD39740BQ33834080-87348D61-7773-443E-9919-AF4070ED4CEFQ33991275-D9598AB1-5AB0-4BEC-A0C3-DDA4E64E38ABQ35890691-47945FE1-1E3C-4E74-813A-EB71333A9A05Q36974459-F4E260F5-F05D-4F9A-A8D0-D7A37103ECF6Q36994186-83B29BCD-F129-4544-A725-FD7E748444EDQ37383943-3C1BB8B8-45E6-4D53-9BB4-013CD5A36864Q39045585-D0EE9076-476C-449C-8E5A-3B3B9099A7ECQ50870760-A0B56CBB-E588-4F1D-B9CC-E5ABC60E6A90Q52646693-890B181F-B6B6-44D1-9BA3-4B49C411D280Q53094795-86FD2373-A6A3-4B92-A458-B92DCD9B69C4Q54107114-E50846DE-670B-4944-8B29-0B557DAC657FQ58035054-5BD90AC5-5FC7-4611-AE8C-4D797704F523
P2860
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular pharmacodynamics of ...... ell lines and xenograft models
@en
Molecular pharmacodynamics of PM02734
@nl
type
label
Molecular pharmacodynamics of ...... ell lines and xenograft models
@en
Molecular pharmacodynamics of PM02734
@nl
prefLabel
Molecular pharmacodynamics of ...... ell lines and xenograft models
@en
Molecular pharmacodynamics of PM02734
@nl
P2093
P2860
P1476
Molecular pharmacodynamics of ...... ell lines and xenograft models
@en
P2093
José Jimeno
Miguel Aracil
Roman Perez-Soler
Yi-He Ling
P2860
P304
P356
10.1016/J.EJCA.2009.03.003
P577
2009-04-05T00:00:00Z